Study summary

Adding a targeted pill to immunotherapy did not beat chemotherapy as a first treatment

LEAP-001 trial · 842 people, phase 3 · Published November 2024, Journal of Clinical Oncology

What was tested

Lenvatinib plus pembrolizumab, against chemotherapy, as first treatment for advanced endometrial cancer, mostly in mismatch-repair-proficient tumors.

What they found

Time before growth and survival were no better than chemotherapy in the main (pMMR) group.
Serious side effects were more common (79% vs 67%).

What it means

A reminder that a combination proven later-line (after chemo fails) doesn't always work as a first treatment. Chemo plus immunotherapy remains the standard.

J Clin Oncol, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.